Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.marksanspharma.com | |
Market Cap | 2,850.40 Cr. | |
Enterprise Value(EV) | 2,602.11 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 4.39 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 14.34 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 33.61 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 26.53 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.37 | Calculated using Price: 62.95 |
Dividend Yield | 0.40 | Period Ending 2022-03 |
No. of Shares Subscribed | 45.32 Cr. | 453,163,746 Shares |
FaceValue | 1 | |
Company Profile | ||
Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005. |
1 Day |
|
-1.64% |
1 Week |
|
-6.33% |
1 Month |
|
+4.83% |
3 Month |
|
+26.81% |
6 Month |
|
+28.24% |
1 Year |
|
+11.52% |
2 Year |
|
+15.73% |
5 Year |
|
+40.87% |
10 Year |
|
+2010.74% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 73.02 | 45.15 | 20.45 | 2.59 | 7.92 | 15.88 | 20.49 | 31.33 | 18.72 | |
Return on Capital Employed (%) | 38.30 | 44.64 | 23.16 | 3.99 | 10.60 | 18.51 | 25.57 | 39.76 | 23.82 | |
Return on Assets (%) | 16.52 | 19.21 | 11.86 | 1.54 | 4.83 | 10.49 | 14.17 | 22.40 | 13.04 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 142 | 380 | 454 | 433 | 471 | 542 | 636 | 887 | 1,202 | 1,263 | |
Non Curr. Liab. | 22 | 1 | -2 | 16 | 16 | 17 | 24 | 24 | 57 | 64 | |
Curr. Liab. | 319 | 286 | 259 | 296 | 235 | 233 | 229 | 299 | 356 | 321 | |
Minority Int. | 7 | 8 | 8 | 6 | 10 | 10 | 13 | 19 | 21 | 19 | |
Equity & Liab. | 490 | 676 | 720 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 1,668 | |
Non Curr. Assets | 147 | 167 | 280 | 268 | 280 | 271 | 308 | 325 | 435 | 447 | |
Curr. Assets | 343 | 509 | 440 | 484 | 451 | 531 | 594 | 903 | 1,201 | 1,221 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 490 | 676 | 720 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 1,668 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 630 | 797 | 893 | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,667 | |
Other Income | 7 | 12 | 13 | 19 | 8 | 5 | 0 | 7 | 42 | 58 | |
Total Income | 637 | 809 | 906 | 786 | 921 | 1,005 | 1,135 | 1,383 | 1,533 | 1,725 | |
Total Expenditure | -516 | -621 | -761 | -734 | -834 | -868 | -942 | -1,037 | -1,232 | -1,392 | |
PBIDT | 121 | 188 | 145 | 52 | 87 | 137 | 193 | 346 | 301 | 333 | |
Interest | -19 | -16 | -10 | -7 | -10 | -10 | -9 | -8 | -8 | -10 | |
Depreciation | -16 | -16 | -28 | -30 | -27 | -23 | -27 | -36 | -45 | -55 | |
Taxation | -13 | -44 | -24 | -4 | -14 | -24 | -36 | -64 | -61 | -69 | |
Exceptional Items | |||||||||||
PAT | 74 | 112 | 83 | 11 | 36 | 80 | 121 | 239 | 187 | 198 | |
Minority Interest | -2 | -3 | -4 | -3 | -3 | -4 | -4 | -3 | -2 | 1 | |
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 72 | 109 | 79 | 9 | 33 | 76 | 117 | 236 | 185 | 199 | |
Adjusted EPS | 2 | 3 | 2 | 0 | 1 | 2 | 3 | 6 | 5 | 5 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 39 | 65 | 155 | 31 | 14 | 50 | 27 | 233 | 179 | 99 | |
Cash Fr. Inv. | -5 | -4 | -33 | -123 | -21 | -39 | -13 | -60 | -45 | -42 | |
Cash Fr. Finan. | -40 | -29 | 17 | -58 | -3 | 3 | -21 | -114 | -15 | 80 | |
Net Change | -7 | 31 | 138 | -150 | -10 | 15 | -7 | 60 | 118 | 137 | |
Cash & Cash Eqvt | 16 | 47 | 185 | 35 | 25 | 40 | 33 | 94 | 212 | 349 |
Tue, 24 Jan 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Investors Meet |
Tue, 24 Jan 2023
Submission Of Certificate From Statutory Auditor In Terms Of Regulation 169(5) Of The Securities And Exchange Board Of India (Issue Of Capital And Disclosure Requirements) Regulations 2018 Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 |
Mon, 23 Jan 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Marksans Pharma Limited announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution. |
Wed, 25 Jan 2023 |
|
|
|
|
|